Endometrial cancer (EC) is among the most common gynecological cancers in developed countries. 1,2 Owing to a slower course compared to other gynecological cancers, the curing possibility is high with early diagnosis and treatment. Adjuvant chemotherapy or radiotherapy is not needed in many cases with early surgery. 3 Two histological categories differ among EC in terms of incidence, response to hormones, and clinical behavior. 4 Type I tumors are generally Grade 1 and 2 tumors, with 80% of EC belonging to this category. These tumors generally have a good prognosis. Type II tumors constitute approximately 20% of EC. These include endometrioid Grade 3 and non-endometrioid tumors. Examples of these are serous, clear cell, mucinous, squamous, and undifferentiated histological types. Grade is ex-tremely important in determining prognosis, and Grade 3 endometrioid EC is responsible for most deaths. 5 The serous is the second most common type of EC with a rather poor prognosis and high risk of metastasis. 6,7 The degree of myometrial invasion and cervical and lymph node involvement are critical considerations in staging. Although transvaginal ultrasonography and magnetic resonance imaging can be utilized for staging, they may be inefficient in detecting lymph node metastases. Therefore, a complete staging is achieved by comprehensive surgical staging. Thus, cervical, adnexal, peritoneal, and lymph node metastases can be evaluated more accurately. The clinicians decide the treatment based on the pathological prognostic factors used in risk classification systems. [8][9][10] This can be used to estimate the 121 121 121